“`html
Mediterrania Capital Partners Exits Akdital: A Landmark Deal in Moroccan Healthcare
Table of Contents
Is teh future of healthcare in emerging markets being shaped by private equity? The recent full exit of mediterrania Capital Partners (MCP) from Akdital, a leading Moroccan private clinic group, suggests a resounding “yes.” This move, finalized on April 25, 2025, marks the culmination of a five-year investment and signals meaningful growth potential in the North African healthcare sector.
Mediterrania Capital Partners (MCP) finalized its release from the capital of the Moroccan group Akdital, specializing in the management of private clinics. The investment fund, based in Malta, has announcement On Friday April 25, 2025, the sale of all 10.5% of the shares he still held in the company.
The Exit Strategy: A Phased Approach
MCP’s departure wasn’t a sudden event.It was a carefully orchestrated, phased exit that maximized returns while ensuring Akdital’s continued stability and growth.
The exact amount of this transaction was not made public. This complete outing comes three years after a frist partial transfer operation, carried out in December 2022, on the occasion of the AKDITAL IPO on the Casablanca market.
In December 2022, Akdital launched its IPO on the Casablanca market, providing MCP with an opportunity for a partial exit. The fund sold 66,670 shares at 3,000 dirhams each, recovering approximately 200 million dirhams – nearly 80% of its initial 250 million dirham investment made in 2020.
On this occasion, the fund had sold 66,670 shares, at the unit price of 3000 dirhams, including a nominal value of 100 dirhams and a emission bonus of 2900 dirhams. This sale had allowed him to recover around 200 million dirhams, or almost 80% of his initial investment of 250 million dirhams in 2020.
Final Exit: Completing the Cycle
The final act came on April 25, 2025, with the sale of the remaining 10.5% stake. While the exact financial details remain undisclosed, the move signifies MCP’s confidence in Akdital’s future and the overall health of the Moroccan healthcare market.
Akdital’s Growth Trajectory: A Story of Success
MCP’s investment in Akdital proved to be a winning formula. The hospital group has experienced substantial growth, solidifying its position as the leading private healthcare operator in Morocco.
Since the investment of MCP, AKDITAL has established itself as the first private health operator in Morocco, under the direction of its founder and CEO, Rochdi Talib.
Financial Performance: Remarkable Gains
Akdital’s financial performance in 2024 speaks volumes about its success. the group reported a 55% increase in turnover,reaching 2,954 million dirhams. EBITDA soared by 64% to 839 million dirhams, with an improved margin of 28.4%. Consolidated net profit jumped by 76% to 348 million dirhams,while the group’s net profit (RNPG) reached 315 million dirhams.
In 2024, he recorded a notable progression of his financial indicators. Turnover has established 2954 million dirhams,up 55% compared to the previous year. the EBITDA reached 839 million dirhams, representing an increase of 64%, with an enhancement in its margin going from 26.8% in 2023 to 28.4% in 2024. The consolidated net profit amounted to 348 million Dirhams, increasing by 76%. The group’s net profit (RNPG) reaches 315 million dirhams.
Capital increase: Fueling Future Expansion
In July 2024
Private Equity and Healthcare in Morocco: Expert Insights on Mediterrania Capital’s Exit from Akdital
Time.news: Today, we’re diving into a critically important development in the Moroccan healthcare sector: Mediterrania Capital Partners’ (MCP) exit from Akdital, a leading private clinic group. to help us understand the implications, we have Dr. Amina Benali, a leading expert in healthcare investment in emerging markets. Dr.Benali, welcome!
Dr. Benali: Thank you for having me.
Time.news: Let’s start with the basics. What’s the meaning of Mediterrania Capital Partners exiting Akdital?
Dr. benali: This exit, finalized on April 25, 2025, is a strong indicator of the increasing maturity and attractiveness of the Moroccan healthcare market, and more broadly North African markets, for private equity investment. MCP’s prosperous exit from Akdital signals that these investments can generate returns and that private healthcare in Morocco is a sector with significant growth potential. Mediterrania Capital Partners focuses on growth investments for smes and mid-cap companies in North Africa and Sub-Saharan Africa [[1]]
Time.news: The exit strategy was a phased approach, beginning with an IPO in December 2022. Can you explain why MCP chose this method?
Dr. Benali: A phased exit, starting with an IPO, is a common strategy in private equity. The IPO on the Casablanca Stock Exchange allowed MCP to realize a significant portion of their investment while also allowing Akdital to access capital for further expansion. The initial share sale recovered nearly 80% of their initial investment, demonstrating the health of Akdital and investor confidence. This staged approach also helps to maintain stability within the company during the transition.It’s worth noting that while the IPO was successful and over-subscribed, Akdital’s share price experienced a decline shortly after [[2]] which is not entirely uncommon and can be attributed to various market factors post-IPO.
Time.news: What does Akdital’s growth trajectory tell us about the state of private healthcare in Morocco?
Dr. Benali: Akdital’s financial performance in 2024, reveals a thriving private healthcare market in Morocco. Very successful indicators such as a 55% increase in turnover and a 76% jump in consolidated net profit, demonstrate robust growth, solidifying the group’s position as the leading private health operator in Morocco [[1]].
Time.news: You touched on investment opportunities. What advice would you give to investors looking at the Moroccan healthcare market?
Dr. benali: Morocco’s private equity sector has witnessed significant growth, investment reached record levels in 2021 [[3]] ,signifying the growing interest in this marketplace.. My advice would be to conduct thorough due diligence, focusing on companies with strong management teams, clear growth strategies, and a commitment to quality care. It’s also crucial to understand the regulatory landscape and the specific needs of the Moroccan population. Consider focusing on specialized areas within healthcare, such as diagnostics or specialized treatments, where demand might potentially be particularly high.
Time.news: Dr. Benali, that’s been incredibly insightful. thank you for sharing your expertise with us today.
Dr. Benali: My pleasure. Thank you for having me.